Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Agena Bioscience
In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.
Researchers discussed ways to ensure COVID-19 diagnostics work for all variants during a recent webinar.
Agena Bioscience will launch two diagnostic panels for targeted testing of lung and colon cancer in Europe in January. The liquid biopsy technology is based on its benchtop mass spectrometer, the MassArray Dx Analyzer 4.
The use of mass spectrometry in IVD applications looks to be gaining momentum. In this article, Alina Kim, Sunayana Karra and Akash Kundu of Boston Biomedical Consultants report on new developments and innovations showcased at the American Association for Clinical Chemistry Annual (AACC) & Clinical Lab Expo (CLE) annual meeting that took place this summer. Players at the convention exhibited a range of Class I medical devices, research use only liquid chromatography tandem mass spectrometry (LC-MS/MS), matrix-assisted laser desorption/ionization (MALDI-TOF), inductively coupled plasma mass spectrometry (ICP-MS), sample preparation automation platforms, and software solutions.
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Drug Discovery Tools
- Other Names / Subsidiaries
- Mesa Laboratories Inc.
- Sequenom Bioscience